Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis

Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3

(2012) Kuen-Feng Chen et al.   BIOCHEMICAL PHARMACOLOGY

Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study

(2012) Ming-Zhi Hao et al.   Chinese Journal of Cancer

Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection

(2011) Tong Ding et al.   CANCER

The Evolution of Endothelial Regulatory Paradigms in Cancer Biology and Vascular Repair

(2011) J. W. Franses et al.   CANCER RESEARCH

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

(2011) K. B. Kim et al.   CLINICAL CANCER RESEARCH

Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer

(2011) J. Taeger et al.   MOLECULAR CANCER THERAPEUTICS

Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration

(2010) Ji-An Chen et al.   Hepatology International

Stimulation of Platelet-derived Growth Factor Receptor β (PDGFRβ) Activates ADAM17 and Promotes Metalloproteinase-dependent Cross-talk between the PDGFRβ and Epidermal Growth Factor Receptor (EGFR) Signaling Pathways

(2010) Karen Mendelson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection

(2010) Zhi Y Chen et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Hepatocellular carcinoma: a global view

(2010) Ju Dong Yang et al.   Nature Reviews Gastroenterology & Hepatology

Major achievements in hepatocellular carcinoma

(2009) Jordi Bruix et al.   LANCET

Role of sorafenib in HCC patients with compromised liver function

(2009) Massimo Di Maio et al.   Nature Reviews Clinical Oncology

Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma

(2009) Yan Gu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivo

(2008) D. Huang et al.   CANCER RESEARCH

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Distinct Angiogenic Mediators Are Required for Basic Fibroblast Growth Factor– and Vascular Endothelial Growth Factor–induced Angiogenesis: The Role of Cytoplasmic Tyrosine Kinase c-Abl in Tumor Angiogenesis

(2008) Wei Yan et al.   MOLECULAR BIOLOGY OF THE CELL

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE